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Quitline in smoking cessation:
A cost-effectiveness analysis
Tanja Tomson
´Asgeir R. Helgason
Hans Gilljam
Center for Tobacco Prevention
Objectives: The cost-effectiveness of the Swedish quitline, a nation-wide, free of charge
service, is assessed.
Methods: The study was based on data of a sample of 1,131 callers enrolled from
February 1, 2000 to November 30, 2001. Outcome was measured as cost per quitter and
cost per year of life saved. Cost per quitter was based on a calculation of the total cost of
the quitline divided by the number of individuals who reported abstinence after 12 months.
The cost per life year saved (LYS) was calculated by the use of data from the literature on
average life expectancy for smokers versus quitters, the total cost of the quitline, and the
cost of pharmacological treatment.
Results: The number of smokers who used the quitline and reported abstinence after
1 year was 354 (31 percent). The accumulated number of life years saved in the study
population was 2,400. The cost per quitter was 1,052–1,360 USD, and the cost per life
year saved was 311–401 USD. A sensitivity analysis showed that, for outcomes down to
an abstinence rate of 20 percent, the cost per LYS rose modestly, from 311 to 482 USD.
Discounting the cost per LYS showed the cost to be 135 USD for 3 percent and 283 USD
for 5 percent.
Conclusions: The Swedish quitline is a cost-effective public health intervention
compared with other smoking cessation interventions.
Keywords: Quitline, Smoking cessation, Cost-effectivenes
Tobacco smoking is the single, largest, preventable and treat-
able public health problem (10;11). Numerous measures
are used for tobacco prevention—legislation, bans, fiscal
policies/pricing, campaigns, educational programs—and for
cessation—counseling and cognitive behavior therapy,
pharmaceuticals, hypnosis, and acupuncture. Many of these
interventions have been assessed for effectiveness (6;17), and
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some for their cost-effectiveness (8;14;19;22). It is widely
acknowledged that the majority of smoking cessation meth-
ods are both effective and cost-effective (6;23). Telephone
helplines (quitlines) have gained increased recognition as
effective interventions for smokers (17;24). The promising
results have led to a rapid proliferation of helplines, ranging
from simple call centers to sophisticated, integrated services.
However, quitlines have not yet been evaluated for their cost-
effectiveness.
The Swedish quitline was established in 1998 as a na-
tionwide free of charge service. By 2001, it was operating
51 hours per week through three to four telephone lines.
When the service is closed, or all lines are busy, an an-
swering machine and a 24-hour interactive voice response
serve as back-up. All calls are registered on computerized
patient records (7). The reported quit rate of the Swedish
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Table 1. Age and Sex Distribution in Our Sample and for All Quitline Callers During the Study Period
Age Age Male Male Female Female Total Total
Age (yr) sample (%) quitline (%) sample n (%) quitline n (%) sample n (%) quitline n (%) sample n (%) quitline n (%)
≤20 2 8 1 (0) 137 (12) 17 (2) 182 (6) 18 (2) 319 (8)
21–30 12 14 17 (8) 145 (13) 115 (13) 436 (15) 132 (11) 581 (14)
31–40 20 20 27 (12) 176 (16) 199 (22) 647 (23) 226 (20) 823 (21)
41–50 23 21 44 (20) 231 (21) 211 (23) 598 (21) 255 (23) 829 (21)
51–60 26 22 72 (32) 239 (21) 227 (25) 648 (22) 299 (26) 887 (22)
61–70 14 11 46 (20) 129 (11) 115 (13) 294 (10) 161 (14) 423 (10)
≥71 3 4 19 (8) 66 (6) 21 (2) 93 (3) 40 (4) 159 (4)
Total 100 100 226 1,123 905 2,898 1131 4,021
quitline is 31 percent, similar to the results achieved in other
nonrandomized trials (5). The aim of this study is a cost-
effectiveness analysis of this Swedish quitline.
MATERIAL AND METHODS
The perspective of this study is on the cost of the Swedish
quitline over 2 years in relation to the number of quitters
during the same time and to available data about life years
saved for those who quit smoking. All costs are considered
fixed because the budget for the quitline is related to a fairly
steady number of people reached by the services over time.
No calculations were made of potential future cost sav-
ings due to decreased demand of medical care for those who
quit. The reason for this strategy is (i) the poor precision
by which future potential cost savings can be estimated, and
(ii) to exercise caution in calculating the cost-effectiveness of
the quitline.
Patients Enrolled in the Study
The total number of calls during the study period was 13,763,
including 8,503 new callers. Of the latter, 4,021 were reg-
istered in the database and 1,131 agreed to participate in
the study, that is, to be subjected to follow-up 1 year later
(Table 1). The majority of callers were women (80 percent).
For callers signing up for counseling, name, address,
gender, age, tobacco use, and individual aspects of smoking
behavior, were registered. One year after the first contact, all
consenting patients received a detailed, fourteen-item follow-
up questionnaire (7). The age and sex distribution in the quit-
line as a whole compares well with the sample’s, with two
exceptions: there are fewer men than women in the youngest
age group (<20 years old) and more men in the 61-to
70-year-old age group.
Cost Calculations
The cost calculations are based on the following sources:
(i) data recorded for 4,021 patients calling the Swedish
quitline during a 22-month period (from February 2000 to
November 2001); (ii) cost data obtained from the financial
records of the Center for Tobacco Prevention, the operator of
the quitline; (iii) official data on life expectancy for different
age groups in Sweden (16); (iv) life expectancy data for
smokers and quitters from a large cohort study in the United
States (18); (v) review of published studies on smoking ces-
sation for data about costs (8;13;15;20); (vi) cost of phar-
macological treatment for smoking cessation paid for by the
patients (Apoteket AB Pricelist OTC Pharmaceuticals 2002).
Cost of Quitline
The total cost of the services provided by the quitline over
the 22-month study period was 0.7 million USD (Table 2).
The dominant cost item of the quitline was salaries including
social overheads.
The second largest cost item summarized as “cost of
services” includes rent of office premises, equipment, infor-
mation technology services, printing, advertising, telephone,
fax, travel, cleaning, and cost of consultants. Cost of mate-
rial includes office supplies, library service, forms, station-
ary, and miscellaneous costs. The cost of nicotine replace-
ment was calculated from self-reported use at the 12-month
follow-up. The average cost per person per day was 1.2 USD.
Prescriptions of bupropion (Zyban®) were reported in seven-
teen cases with a per capita cost of 101 USD. The total cost
of the pharmacological treatment for the study population
was 45,772 USD.
Life Expectancy
Life expectancy for men and women in Sweden was calcu-
lated from official statistics (16), see Table 5. To calculate
life expectancy for smokers and quitters, data from a longi-
tudinal cohort study in the United States was used (18). Data
Table 2. Distribution of Costs for the Swedish
Quitline in SEK and USD During the Study
Period February 2000–November 2001
SEK USD
Personnel costs 4,618,553 475,095
Material 231,034 23,766
Services 1,947,976 200,382
Total 6,797,563 699,243
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Table 3. Gain in Life Expectancy for Smokers
Who Quit at Different Ages (15)
Gain in life ExpectancyaQuit smoking
at age (yr) women men
35 7.7 8.5
45 7.2 7.1
55 5.6 4.8
65 5.1 2.0
a Taylor et al. (18). It is here assumed that the average number
of life years saved between 14 and 35 years of age also will
be 8 years.
for quitters before the age of 35 were not reported in the U.S.
study (Table 3).
Measurement of Outcome
Quitter/Abstinence. Abstinence was defined as not a
single puff of smoke 7 days before follow-up by self-report.
This strategy has been found to be an accurate measurement
of abstinence (9) and was selected for practical and econom-
ical reasons.
Life Years Saved—LYS. The ultimate aim of preven-
tion, treatment, and rehabilitation is improvement in health;
reduced mortality and morbidity, and improved or maintained
quality of life. Although the link between an intermediate
outcome measure such as number of quitters, and the ulti-
mate aim of smoking cessation is known, there is an argu-
ment for calculating life years saved or quality adjusted life
years saved. This process makes it possible to illustrate the
relative effectiveness of different interventions for health im-
provement. We used life years saved (LYS) as an outcome
measure.
Measurement of Cost-Effectiveness
The cost per quitter enrolled in the quitline was calculated
as the total cost of the quitline divided by the number of
individuals who were abstinent after 12 months. In Figure 1,
a more conservative approach has been taken into account
Figure 1. Distribution context for calculations with a more “realistic approach.” It is assumed here that 7% are spontaneous
quitters, 23% of those calling the quitline quit before first call, 70% will relapse, and that 45% will be helped.
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Table 4. Cost-Effectiveness of Smoking Cessation Inter-
ventions
Smoking cessation Cost per life year gained
intervention in USD year 2002 (ref.)
Telephone counseling 311–401 (current study)
Swedish quitline
Quit &Win 235–1528a (20)
Community antismoking 950a (15)
campaign
Brief advice 282a (8)
Advice + self-material 358a (8)
General practitioner 949a (8)
counseling
Bupropion (SR) 10,520 (13)
NRT 12,047 (13)
NRT + bupropion (SR) 19,492 (13)
a Recalculated according to CPI; Source: Department of Labor, Bureau of
Labor Statistics, & OECD Main Indicators CPI.
NRT, nicotine replacement therapy; SR, sustained release; CPI, Consumer
Price Index.
assuming 274 (24 percent) being abstinent after 1 year
and, thus, taking into consideration the spontaneous quitters
(7 percent), those who already had stopped before first call
(23 percent), those relapsing (70 percent), and those who
will be helped (45 percent). The cost per life year saved was
calculated by dividing the total cost of the quitline including
the cost of pharmacological treatment for smoking cessation
by life years saved. Table 4 provides examples of the relative
cost-effectiveness, expressed in cost per year of life saved,
of different smoking cessation measures; brief advice (8),
Quit & Win contest (20), advice and self-material (8), gen-
eral practitioner counseling (8), antismoking campaign (15),
pharmacotherapies (13), and the Swedish quitline (Table 4).
For currency conversion from SEK to USD, we used an
average exchange bank rate for 2002 of 9.721 (The Riksbank
average exchange rate. www.riksbank.se). The average ex-
change rate for year 2002 from Pound Sterling to USD was
1.432 (www.statistics.gov.uk). All prices were recalculated
according to the Consumer Price Index up to the same year,
2002.
Sensitivity Analysis
Quit rate and life years saved may vary depending on the
validity of findings in other studies. The robustness of the
results, therefore, may be tested in a sensitivity analysis (4).
In this analysis, the data used for quit rate and life
years saved are varied to determine whether the results will
change significantly. Thus in our sensitivity analysis, we re-
calculated the cost-effectiveness ratios by reducing life years
gained from an average of 8 years to an average of 6, 4, and
2 years, respectively (3). Likewise, we recalculated the cost-
effectiveness of reducing the rate of quitters from 30 percent
to 25, 20, 15, 10, 7, and 6 percent, respectively.
Discounting
Discounting LYS has important implications when compar-
ing cost per year of life saved between different investments
or different programs. In some cases, costs are incurred
immediately and remain undiscounted. In our study, costs
are discounted at 3 percent and 5 percent over the 2-year
(22-month) period of the study. Benefits are discounted by
two alternative rates: 3 percent and 5 percent and are based
upon someone who quit by the age of 35 and who after these
years will gain 8 years in life expectancy. Life expectancy
is extended from 72–80 years. We also calculated the undis-
counted rate (0 percent) of the benefits. The calculations are
based on the cost per life years saved for the quitline. The
state of the art suggests that benefits should be treated in
the same way as costs, and discounted at the same rate (4).
Ethical approval was obtained by Karolinska Institutet Dnr
00-367.
RESULTS
A total of 4,021 individuals received tobacco cessation coun-
seling over the study period. Often, they were advised on sin-
gle aspects such as nicotine replacement therapy or smoke-
less tobacco. Of the 4,021, 1,131 subjects enrolled in the
evaluation. After 1 year, 354 (31 percent) smokers reported
abstinence. The cost per quitter for the Swedish quitline was
between 1,052 and 1,360 USD.
In Table 5, the accumulated life years saved for each
group is presented. These are divided with the total cost of
the quitline, including pharmaceuticals. The accumulated life
years gained was 2,400, and the cost per life year saved is
equivalent to 311–401 USD (Figure 1).
As shown in Table 6, the lowest quit rate corresponds
to 1,607 USD per LYS and the highest to 311 USD. For
outcomes down to 20 percent abstinence, the cost per year of
life saved changed modestly (from 311 to 482 USD).
The sensitivity of the data on life years saved was tested
by calculating the effects of 2, 4, and 6 life years saved,
instead of an average of 8 life years saved (Table 5). The lower
value, 2 years of life saved, increased the cost of the quitline
from 311 USD to 1,056 USD per LYS. When changing to
4 years, the cost per LYS was 526 USD and for 6 years,
355 USD.
Without a discount rate (0 percent), the cost per life year
saved was 39 USD. Using a discount rate of 3 percent and
5 percent gives a cost per LYS at 135 and 283 USD, respec-
tively. The discounted costs was 689,104 USD for 3 per-
cent and 682 461 for 5 percent.
DISCUSSION
To our knowledge, this report is the first published study
evaluating the relative cost effectiveness of a quitline. The
cost per life year saved of the Swedish quitline was estimated
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Table 5. Results of Sensitivity Analysis Assuming 2, 4, and 6 LYS
Gain in life Gain in life
Women Life expectancy Men who Life expectancy
Age who quit expectancyb according to 2 LYS 4 LYS 6 LYS quit after expectancyb according to 2 LYS 4 LYS 6 LYS
groupsa after 1 women Taylorc women women women women 1 year men Taylorc men men men men
(yr) year (n) (yr) (yr) (yr) (yr) (yr) (n) (yr) (yr) (yr) (yr) (yr)
14–19 1 65 8 2 4 6 0 61 0 0 0 0
20–24 10 61 80 20 40 60 2 56 16 4 8 12
25–29 20 56 160 40 80 120 2 51 16 4 8 12
30–34 28 51 224 56 112 168 4 47 32 8 16 24
35–39 33 46 254 66 132 198 4 42 34 8 16 24
40–44 34 41 262 66 136 204 6 37 51 12 24 24
45–49 38 36 274 76 152 228 6 32 51 12 24 24
50–54 43 32 310 86 172 258 7 28 50 14 28 42
55–59 32 27 179 64 128 192 16 23 77 32 64 96
60–64 25 23 140 50 100 150 11 19 53 22 44 66
65–69 11 18 56 22 44 66 4 15 8 8 16 24
70–74 8 15 41 16 32 48 5 12 10 10 20 30
75–80 2 11 10 4 8 12 2 9 4 4 8 12
285 1,998 568 1,140 1,710 69 402 138 276 390
a We used 5-year age groups in our calculations, and the statistics of life expectancy were adjusted accordingly. In both cases (men and women), we used
mean values.
b Statistics Sweden 2001.
c Taylor et al. (18).
LYS, life year saved.
to between 311 and 401 USD (Table 6). The cost per quitter
ranged between 1,052 and 1,360 USD. The higher figures
are based on a more “realistic approach” compensating for
the spontaneous quitters and those who already had stopped
before first call (Figure 1). It is known that other smoking
cessation interventions (Table 4) are highly cost-effective
in terms of the cost per LYS (8;14;22) as compared with
most medical interventions and prevention programs (19).We
measured effectiveness using LYS (4). Our life expectancy
calculations (Table 3) were based on the study by Taylor
et al. (18), known to have a larger and more comprehensive
sample than others (21), enabling us calculations for different
ages.
Our study is based on data collected from a program
that is run in a real-life situation as opposed to a random-
ized clinical trial. First, it may be argued that the individuals
in our sample were more motivated to quit smoking than
Table 6. Sensitivity Analysis
Abstinent after Cost per life year
12 months (%) saved USD
6% 1,607
7% 1,375
10% 963
15% 642
20% 482
25% 385
30% 321
31% 311
the average smoker. Callers to a quitline who do not get
the requested support are reported to have a spontaneous
12-month quit rate of 7 percent (25) compared with the
2–3 percent spontaneous quit rate seen annually in the gen-
eral smoking population (6). Second, 23 percent of the callers
in this study had stopped smoking immediately before first
contact (1–4 days) and called as they feared an impending
relapse. The relapse rate is believed to be very high in this
group, but with our support, their 12-month abstinence rate
was 50 percent (128/256), which was 50 percent higher than
that of the other callers. Third, our definition of abstinence
at 12-month follow-up, although widely used, does not guar-
antee life-long abstinence (12).
As shown in Table 6, we used 6 percent as the lowest
quit rate in our sensitivity analysis. This yields a cost of 1,607
USD as compared with 311 USD per year of life saved for the
354 (31 percent) abstinent smokers. Thus, the argument that
the ratio of cost to effectiveness is sensitive to the quit rate is
valid. However, the results in terms of cost per quitter and cost
per life years saved remain cost-effective in comparison with
several other measures for smoking cessation. The results
also show that even “pessimistic” estimates of the quit rate
compare favorably with other health-care interventions (13).
Our method does not enable assessment of possible fu-
ture benefits, in terms of cost savings due to less consumption
of medical care, decreased productivity losses due to sick-
leave and smoking breaks (22), and the excess costs of passive
smoking in the unborn child, children, and adults (26).
Mortality is used as an end point. However, smoking
cessation also leads to a compression of morbidity and
INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 20:4, 2004 473
Tomson et al.
improvement in quality of life (1), which is not included
here. The uncertainty around these future benefits may cause
an underestimation of the effectiveness of the quitline.
To use U.S. data for assessing life expectancy for
Swedish smokers and quitters introduces a potential bias.
However, the smoking panorama in Sweden does not differ
much from that of the United States and other rich countries.
Abstinence was not biochemically validated, but the Na-
tional Health Survey has concluded that self-reported smok-
ing status among respondents is reliable. Among reported
nonsmokers, only 1.4 percent had serum cotinine >15.0 ng/
ml, the selected cut-off point for identifying smokers in their
report (2).
POLICY IMPLICATIONS
This study supports the supposition that smoking cessation
telephone quitlines can be particularly cost-effective health
interventions and strongly suggests that they should be part
of comprehensive, publicly funded, national tobacco control
programs.
REFERENCES
1. Brønnum-Hansen H, Juel K. Abstention from smoking ex-
tends life and compresses morbidity. A population based study
of health expectancy among smokers and never smokers in
Denmark. Tob Control. 2001;10:273-278.
2. Caraballo RS, Giovino GA, Pechacek TF, Mowery PD. Fac-
tors associated with discrepancies between self-reports on
cigarette smoking and measured serum cotinine levels among
persons aged 17 years and older. Third National Health and
Nutrition Examination Survey, 1988-1994. Am J Epidemiol.
2001;153:807-814.
3. Crealey GE, McElmay JC, Maguire TA, O’Neill C. Costs and
effects associated with a community pharmacy-based smoking
cessation program. Pharmacoeconomics. 1998;14:323-333.
4. Drummond MF, O’Brian B, Stoddart GL, Torrance GW. Meth-
ods for the economic evaluation of health care programs. 2nd
ed. Oxford: Oxford University Press; 1997.
5. El-Bastawissi AY, McAfee T, Zbikowski SM, et al. The unin-
sured and Medicaid Oregon tobacco user experience in a
real world, phone based cessation programme. Tob Control.
2003;12:45-51.
6. Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use
and dependence. A clinical practice guideline. Rockville, MD:
U.S. Department of Health and Human Services. Public Health
Service; 2000.
7. Helgason A, Tomson T, Lund KE, et al. Factors related to
abstinence in a telephone helpline for smoking cessation. Eur
J Public Health. 2004;14:306-310.
8. Parrot S, Godfrey C, Raw M, et al. Guidance for commissioners
on the cost effectiveness of smoking cessation interventions.
Thorax. 1998;53 (Suppl 5):1-38.
9. Patrick DL, Cheadle A, Thompson DC, et al. The validity of
self-reported smoking: A review and meta-analysis. Am J Pub-
lic Health. 1994;84:1086-1093.
10. Peto R, Lopez AD, Boreham J, Thun M, Heath C. Mortality
from tobacco in developed countries 1950-2000: Indirect esti-
mates from national vital statistics. Oxford: Oxford University
Press; 1994.
11. Peto R. Smoking and death: The past 40 years and the next 40.
BMJ. 1994;309:937-939.
12. Pierce JP, Gilpin EA. A minimum 6-month prolonged absti-
nence should be required for evaluation smoking cessation tri-
als. Nicotine Tob Res. 2003;5:151-153.
13. Rapid and systematic review for NICE Bupropion SR and
NRT for smoking cessation, 2002. Available at: www.nice.org.
uk/pdf/Buproprionreview.pdf.
14. SBU—The Swedish Council on Technology Assessment in
Health Care. Metoder fo¨r ro¨kavva¨njning. [Methods for smok-
ing cessation]. Rapport nr 138, Stockholm: Swedish Council
on Technology Assessment in Health Care; 1998.
15. Shipley RH, Hartwell TD, Austin WD, Clayton AC, Stanley
LC. Community stop-smoking contests in the COMMIT trial:
Relationship of participation to costs. Prev Med. 1995;24:286-
292.
16. Statistics Sweden. SCB lifetables, 2001. Available at: www.
scb.se.
17. Stead LH, Lancaster T, Perera R. Telephone counselling for
smoking cessation. (Cochrane Review) In: The Cochrane
Library, Volume 1. Oxford: Update Software; 2003.
18. Taylor DH, Hasselblad V, Henley SJ, Thun MJ, Sloan FA. Ben-
efits of smoking cessation for longevity. Am J Public Health.
2002;92:990-996.
19. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-
saving interventions and their cost-effectiveness. Risk Anal.
1995;15:369-390.
20. Tillgren P, Rose´n M, Haglund BJ, et al. Cost-effectiveness of
a tobacco ‘quit and win’ contest in Sweden. Health Policy.
1993;26:43-53.
21. Tsevat J, Weinstein MC, Williams LW, Tosteson AN, Goldman
L. Expected gains in life expectancy from various coronary
heart disease risk factor modifications. Circulation. 1991;83:
1194-1201.
22. Warner KE. Cost effectiveness of smoking cessation therapies.
Interpretation of the evidence and implications for coverage.
Pharmacoeconomics 1997;11:538-549.
23. World Bank. Curbing the epidemic: Governments and the eco-
nomics of tobacco control. Washington, DC: The World Bank;
1999;8:196-201.
24. Zhu SH, Anderson CM, Tedeschi GJ, et al. Evidence of real-
world effectiveness of a telephone quitline for smokers. N Engl
J Med. 2002;347:1087-1093.
25. Zhu SH, Melcer T, Sun J, et al. Smoking cessation with and
without assistance a population-based analysis. Am J Prev Med.
2000;18:305-311.
26. Mackay J, Eriksen M. The tobacco atlas. World Health Organ-
isation. London: The Hanway Press; 2002.
474 INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 20:4, 2004
